Clinical Trial

Efficacy and Safety of Tazbentetol in ALS Participants

Name: Efficacy and Safety of Tazbentetol in ALS Participants — clinical trial record (NCT07325591)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

The objectives of this study are to examine the effects of tazbentetol on clinical measures of ALS, patient reported outcomes (PROs), long-term safety and tolerability.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2026-01-07; most recent amendment 2026-02-26.

Trial Details

NCT Number	NCT07325591
Lead Sponsor	Spinogenix
Conditions	Amyotrophic Lateral Sclerosis
Enrollment	430 participants
Start Date	2026-03-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-03-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-02